Skip to main content
Home > The Daily Extra > Company News

Chronological Index of : Company News

 Current Issue
  • COMPANY NEWS: Kadmon, Jinghua enter mAb deal

    Kadmon Corp. LLC (New York, N.Y.) said it granted Jinghua Pharmaceutical Co. Ltd. (Nantong, China) an exclusive license to develop and commercialize Kadmon's human mAbs against VEGF receptor 2 (VEGFR-2; KDR/Flk-1) and …

    Published on 11/25/2015
  • COMPANY NEWS: Teva, Heptares strike migraine deal

    The Heptares Therapeutics Ltd. subsidiary of Sosei Group Corp. (Tokyo:4565) granted Teva Phamaceutical Industries Ltd. (NYSE:TEVA) exclusive, worldwide rights to develop preclinical, small molecule calcitonin gene-…

    Published on 11/25/2015
  • COMPANY NEWS: JAMA study finds Harvoni cost-effective

    A study published Monday in JAMA Internal Medicine found that HCV drug Harvoni sofosbuvir/ledipasvir from Gilead Sciences Inc. (NASDAQ:GILD) was cost-effective across all ranges of disease severity.The study assessed …

    Published on 11/24/2015
  • COMPANY NEWS: Lilly's NSCLC drug among host of approvals

    FDA and EMA each approved multiple drugs early this week, including the first approval for Portrazza necitumumab (LY3012211) from Eli Lilly and Co.(NYSE:LLY). FDA approved Portrazza in combination with chemotherapy as a…

    Published on 11/24/2015
  • COMPANY NEWS: Turing offers hospitals Daraprim discount

    Turing Pharmaceuticals AG (Zug, Switzerland) said it will provide discounts of up to 50% to hospitals on the price of toxoplasmosis drug Daraprim pyrimethamine, but will not cut the drug's list price.The company came …

    Published on 11/24/2015
  • COMPANY NEWS: Uni-Bio, Jiangsu Hansoh in diabetes deal

    Uni-Bio Science Group Ltd. (HKSE:690) gained exclusive, worldwide rights to mitiglinide from Jiangsu Hansoh Pharmaceutical Co. Ltd. (Lianyungang, China). Uni-Bio said China FDA has approved the insulin secretagogue as a…

    Published on 11/24/2015
  • COMPANY NEWS: CVS picks Amgen's Repatha

    CVS Health Corp. (NYSE:CVS) has selected Repatha evolocumab from Amgen Inc. (NASDAQ:AMGN) as its exclusive PCSK9 inhibitor in exchange for undisclosed discounts on the lipid-lowering mAb."We have determined that …

    Published on 11/23/2015
  • COMPANY NEWS: FDA approves Opdivo in RCC

    FDA approved Opdivo nivolumab from Bristol-Myers Squibb Co. (NYSE:BMY) to treat advanced renal cell carcinoma in patients who have received prior anti-angiogenic therapy. The approval came well in advance of the drug's …

    Published on 11/23/2015
  • COMPANY NEWS: Zai gets China rights to Hanmi's EGFR inhibitor

    Hanmi Pharmaceutical Co. Ltd. (KOSDAQ:128940) granted Zai Laboratory Ltd. (Shanghai, China) exclusive rights in China to HM61713 to treat EGFR mutation-positive non-small cell lung cancer (NSCLC). The deal includes …

    Published on 11/23/2015
  • COMPANY NEWS: AZ, Sanofi swap 210,000 compounds

    AstraZeneca plc (LSE:AZN; NYSE:AZN) and Sanofi (Euronext:SAN; NYSE:SNY) said they will exchange 210,000 chemical compounds from their libraries. The partners said no payments were associated with the transfer, and there…

    Published on 11/20/2015
  • COMPANY NEWS: CHMP backs Enbrel biosimilar, UCB epilepsy candidate

    EMA's CHMP recommended approval of Benepali etanercept (SB4) from Samsung Bioepis Co. Ltd., a biosimilar of Enbrel etanercept for a host of autoimmune indications. The committee also recommended approval of Briviact …

    Published on 11/20/2015
  • COMPANY NEWS: Express Scripts to calculate 'blended' drug prices

    Express Scripts Holding Co. (NASDAQ:ESRX) CMO Steve Miller said the company will create a "blended price" for drugs as part of its new indication-based pricing scheme. At an HHS forum on prescription drug pricing, …

    Published on 11/20/2015
  • COMPANY NEWS: FDA approves genetically modified salmon

    FDA approved AquAdvantage Salmon from AquaBounty Technologies Inc. (LSE:ABTX). The Atlantic salmon is genetically engineered to reach market size more quickly than non-genetically engineered farm-raised Atlantic salmon.…

    Published on 11/20/2015
  • COMPANY NEWS: KaloBios names Shkreli CEO, revives leukemia program

    KaloBios Pharmaceuticals Inc. (NASDAQ:KBIO) gained $7.85 (75%) to $18.25 on Friday, continuing its rise after a group led by Martin Shkreli invested in the company. The company named Shkreli chairman and CEO after …

    Published on 11/20/2015
  • COMPANY NEWS: Takeda gets quick FDA nod for MM drug Ninlaro

    FDA approved Ninlaro ixazomib from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) to treat multiple myeloma (MM), months ahead of its March 10, 2016, PDUFA date. The agency approved Ninlaro in combination with Revlimid …

    Published on 11/20/2015
  • COMPANY NEWS: Eiger reverse-merges with Celladon

    Eiger Biopharmaceuticals Inc. (San Carlos, Calif.) will acquire Celladon Corp. (NASDAQ:CLDN) through a reverse merger. Eiger President and CEO David Cory will lead the combined company, which will be named Eiger and …

    Published on 11/19/2015
  • COMPANY NEWS: Ipsen, Interprotein in endocrine disease deal

    Ipsen Group (Euronext:IPN; Pink:IPSEY) and Interprotein Corp. (Osaka, Japan) partnered to develop therapeutic peptides to treat endocrine diseases including Cushing's disease. Ipsen will have an exclusive option to …

    Published on 11/19/2015
  • COMPANY NEWS: Servier, Pfizer split rights to Cellectis' UCART19

    Servier (Neuilly-sur-Seine, France) exercised its option to acquire a worldwide license to UCART19 from Cellectis S.A. (Euronext:ALCLS; NASDAQ:CLLS) and subsequently granted Pfizer Inc. (NYSE:PFE) U.S. rights to the …

    Published on 11/19/2015
  • COMPANY NEWS: Spring Bank, Gilead to test HBV combo

    Spring Bank Pharmaceuticals Inc. (Milford, Mass.) said it will collaborate with Gilead Sciences Inc. (NASDAQ:GILD) to conduct a Phase II trial of Spring Bank's SB 9200 plus Gilead's Viread tenofovir disoproxil fumarate …

    Published on 11/19/2015
  • COMPANY NEWS: FDA accepts BLA for Sandoz's Neulasta biosimilar

    The Sandoz unit of Novartis AG (NYSE:NVS; SIX:NOVN) said FDA accepted a BLA for LA-EP2006, a proposed biosimilar of neutropenia drug Neulasta pegfilgrastim from Amgen Inc. (NASDAQ:AMGN), a pegylated granulocyte colony-…

    Published on 11/18/2015
  • COMPANY NEWS: Genentech, Novartis to share ex-U.S. Fovista rights

    The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) exercised its option to share ex-U.S. rights to wet age-related macular degeneration (AMD) candidate Fovista pegpleranib with Novartis AG (NYSE:NVS; SIX:NOVN). The…

    Published on 11/18/2015
  • COMPANY NEWS: NICE spurns Amgen's Repatha

    The U.K.'s NICE issued draft guidance recommending against the use of Repatha evolocumab from Amgen Inc. (NASDAQ:AMGN), alone or in combination with lipid-lowering therapies, to treat primary hypercholesterolemia or …

    Published on 11/18/2015
  • COMPANY NEWS: AZ prices Tagrisso

    AstraZeneca plc (LSE:AZN; NYSE:AZN) priced non-small cell lung cancer (NSCLC) drug Tagrisso osimertinib (AZD9291) at a wholesale acquisition cost (WAC) of $12,750 per month.AZ spokesperson Michele Meixell said AZ's …

    Published on 11/17/2015
  • COMPANY NEWS: Management tracks

    Hematology and oncology company Nordic Nanovector ASA (OSE:NANO) said CMO Cristina Oliva will resign in January 2016 to pursue other opportunities. The company is searching for a new CMO.Generics and drug delivery play …

    Published on 11/17/2015
  • COMPANY NEWS: Radius stumbles on NDA delay

    Radius Health Inc. (NASDAQ:RDUS) fell $7.67 (11%) to $61.51 on Tuesday after it said it would delay submission of an NDA for osteoporosis treatment abaloparatide-SC (BA058-SC) to the end of 1Q16.On the company's 3Q15 …

    Published on 11/17/2015

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993